PriceTargets.com logo

2seventy bio - TSVT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 186.62%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$3.14 As of 12/20/2024 06:31 PM ET
▲ +0.22 (7.53%)

This chart shows the closing price for TSVT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 2seventy bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TSVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TSVT

Analyst Price Target is $9.00
▲ +186.62% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for 2seventy bio in the last 3 months. The average price target is $9.00, with a high forecast of $18.00 and a low forecast of $2.00. The average price target represents a 186.62% upside from the last price of $3.14.

This chart shows the closing price for TSVT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in 2seventy bio. This rating has held steady since April 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
6/24/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/29/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$7.00 ➝ $6.00
6/27/2024WedbushReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
6/6/2024The Goldman Sachs GroupDowngradeNeutral ➝ Sell$5.00 ➝ $2.00
5/9/2024Canaccord Genuity GroupUpgradeStrong-Buy
5/9/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$12.00 ➝ $11.00
4/8/2024CitigroupBoost TargetBuy ➝ Buy$9.00 ➝ $12.00
3/18/2024WedbushReiterated RatingNeutral ➝ Neutral$5.00
1/31/2024Leerink PartnrsUpgradeMarket Perform ➝ Outperform
1/31/2024TD CowenReiterated RatingOutperform ➝ Market Perform
1/31/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$5.00 ➝ $18.00
11/20/2023WedbushDowngradeOutperform ➝ Neutral
11/14/2023WedbushReiterated RatingOutperform$7.00 ➝ $4.00
10/30/2023Leerink PartnrsDowngradeOutperform ➝ Market Perform
10/30/2023Leerink PartnersDowngradeOutperform ➝ Market Perform$6.00
10/12/2023CitigroupInitiated CoverageBuy$13.00
9/13/2023The Goldman Sachs GroupDowngradeBuy ➝ Neutral$5.00
9/12/2023GuggenheimDowngradeBuy ➝ Neutral
8/15/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$27.00 ➝ $24.00
8/15/2023GuggenheimLower TargetBuy ➝ Buy$27.00 ➝ $26.00
7/28/2023WedbushLower TargetOutperform$26.00 ➝ $22.00
7/28/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$25.00 ➝ $13.00
7/20/2023Morgan StanleyLower TargetOverweight$28.00 ➝ $25.00
5/4/2023WedbushReiterated RatingOutperform$24.00 ➝ $26.00
3/17/2023WedbushLower TargetOutperform$28.00 ➝ $21.00
1/24/2023Morgan StanleyLower TargetOverweight$29.00 ➝ $28.00
1/20/2023The Goldman Sachs GroupBoost TargetBuy$25.00 ➝ $28.00
1/10/2023Leerink PartnersLower TargetOutperform$41.00 ➝ $34.00
11/8/2022Morgan StanleyBoost TargetOverweight$27.00 ➝ $29.00
11/8/2022Leerink PartnersLower TargetOutperform$42.00 ➝ $41.00
10/31/2022GuggenheimInitiated CoverageBuy$30.00
8/15/2022Morgan StanleyLower TargetOverweight$28.00 ➝ $27.00
8/12/2022Canaccord Genuity GroupLower Target$42.00 ➝ $28.00
7/15/2022Morgan StanleyLower TargetOverweight$31.00 ➝ $28.00
5/17/2022Morgan StanleyLower TargetOverweight$31.00
5/2/2022The Goldman Sachs GroupInitiated CoverageBuy$26.00
2/10/2022Leerink PartnersInitiated CoverageOutperform$38.00
1/6/2022CowenInitiated CoverageOutperform
11/8/2021Morgan StanleyInitiated CoverageOverweight$72.00
11/8/2021WedbushInitiated CoverageOutperform$40.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.35 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 7 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

2seventy bio logo
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.14
Low: $2.87
High: $3.19

50 Day Range

MA: $4.11
Low: $2.92
High: $5.21

52 Week Range

Now: $3.14
Low: $2.78
High: $6.40

Volume

900,092 shs

Average Volume

716,138 shs

Market Capitalization

$161.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Frequently Asked Questions

What sell-side analysts currently cover shares of 2seventy bio?

The following sell-side analysts have issued research reports on 2seventy bio in the last year: Canaccord Genuity Group Inc., Citigroup Inc., Leerink Partners, Leerink Partnrs, Morgan Stanley, TD Cowen, The Goldman Sachs Group, Inc., and Wedbush.
View the latest analyst ratings for TSVT.

What is the current price target for 2seventy bio?

0 Wall Street analysts have set twelve-month price targets for 2seventy bio in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 186.6%. Leerink Partners has the highest price target set, predicting TSVT will reach $18.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $2.00 for 2seventy bio in the next year.
View the latest price targets for TSVT.

What is the current consensus analyst rating for 2seventy bio?

2seventy bio currently has 1 sell rating, 3 hold ratings, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TSVT.

What other companies compete with 2seventy bio?

Other companies that are similar to 2seventy bio include Tectonic Therapeutic, Prothena, CARGO Therapeutics, Stoke Therapeutics and Altimmune. Learn More about companies similar to 2seventy bio.

How do I contact 2seventy bio's investor relations team?

The company's listed phone number is 339-499-9300 and its investor relations email address is [email protected]. The official website for 2seventy bio is www.2seventybio.com. Learn More about contacing 2seventy bio investor relations.